Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal

被引：29

作者：

Johnson, AP ^{[1
]}

Livermore, DM ^{[1
]}

机构：

[1] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England

来源：

LANCET | 1999年 / 354卷 / 9195期

关键词：

D O I：

10.1016/S0140-6736(99)00344-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2012 / 2013

页数：2

共 12 条

[1] Streptogramins: an answer to antibiotic resistance in gram-positive bacteria [J].

Leclercq, R ;

Courvalin, P .

LANCET, 1998, 352 (9128) :591-592

[2] A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus [J].

Low, DE ;

Nadler, HL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :53-58

[3] Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections [J].

Moellering, RC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :25-30

[4] The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium [J].

Moellering, RC ;

Linden, PK ;

Reinhardt, J ;

Blumberg, EA ;

Bompart, F ;

Talbot, GH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :251-261

[5]

NADLER H, 1999, CLIN MICROBIOL NEWSL, V13, P103

[6] Optimal treatment of complicated skin and skin structure infections [J].

Nichols, RL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :19-23

[7] Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin [J].

Nichols, RL ;

Graham, DR ;

Barriere, SL ;

Rodgers, A ;

Wilson, SE ;

Zervos, M ;

Dunn, DL ;

Kreter, B .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :263-273

[8] First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [J].

Ploy, MC ;

Grélaud, C ;

Martin, C ;

de Lumley, L ;

Denis, F .

LANCET, 1998, 351 (9110) :1212-1212

[9] Safety and tolerability of quinupristin/dalfopristin: administration guidelines [J].

Rubinstein, E ;

Prokocimer, P ;

Talbot, GH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :37-46

[10] Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides [J].

Tenover, FC ;

Lancaster, MV ;

Hill, BC ;

Steward, CD ;

Stocker, SA ;

Hancock, GA ;

O'Hara, CM ;

Clark, NC ;

Hiramatsu, K .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (04) :1020-1027

← 1 2 →